Lupin Of India Sued In U.S. By Novo Of Denmark Over Diabetes Generic
This article was originally published in PharmAsia News
Executive SummaryIndia's Lupin has been sued by Novo Nordisk over Lupin's effort to market a generic for treating diabetes in the United States
You may also be interested in...
As part of its response to the coronavirus outbreak, the European association representing generic and biosimilar drug companies, Medicines for Europe, has set out a series of policy recommendations that it says could help to mitigate the possible risks to medicines supply.
Podcast: Living In China's Coronavirus Lockdown, Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.